科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective. Bevacizumab, anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody, in combination with chemotherapeutic agents paclitaxel or capecitabine, was approved as first-line treatment for %26quot; triple-negative%26quot; (ER-/PgR-/ HER2-) metastatic breast cancer (mBC). Potential adverse effects of bevacizumab include hypertension, proteinuria, bleeding and thromboembolic events. Because of its toxicity profile, we evaluated the tolerability of bevacizumab and the quality of life in elderly patients with %26quot;triple-negative%26quot; mBC. %26lt;br%26gt;Methods. From January 2009 to March 2011, we studied 43 patients (28 %26lt; 70 years and 15 %26gt;= 70 years) receiving treatment with bevacizumab and paclitaxel. Adverse events were defined according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.02). Quality of life was assessed with the European Organization for Research and Treatment of Cancer (EORTC) and Functional Assessment of Cancer Therapy (FACT) questionnaires. %26lt;br%26gt;Results. Grade 3 hypertension was reported in one patient %26lt; 70 years of age and in 4 patients %26gt;= 70 years. Grade 2 proteinuria occurred in 2 patients in each group. Grade 1 epistaxis was observed in one patient in both groups. One patient %26gt;= 70 years had deep vein thrombosis. The EORTC and FACT questionnaires scores showed no particular impact of adverse events on quality of life of patients. %26lt;br%26gt;Conclusions. In our study, combination therapy with bevacizumab and paclitaxel was well tolerated by all patients. In patients aged %26gt;= 70 years, the incidence of bevacizumab-related adverse events was similar to that observed in younger patients, with the exception of grade 3 hypertension (3,6% vs. 26,7%; p = 0,024).
- 出版日期2012-6
